Les indications de la curiethérapie de prostate par implantation permanente

8Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In the last decade, brachytherapy emerged as a particularly appealing new way of treating localized prostate cancer. Recently published 10-12 years biochemical control results appear to be superimposable to the best percentages achieved by surgery or conformal radiotherapy, with a small percentage of complications. This applied to severely patients. Only patients with T1/T2, PSA < 10 ng/mL, and Gleason score < 7 should be proposed such a treatment. The potential benefit of exploring patients with a endorectal coil MRI is being evaluated. The number of positive biopsies is also a parameter which should probably be considered in the therapeutic choice. Moreover, a prostate volume > 60 g, hip mobility limitations, a urinary obstructive syndrome and previous transuretral resection lead to difficulties in technical implantation and therefore must be taken into account when discussing brachytherapy. In conclusion, for adequately selected patients, brachytherapy offers a particularly applied alternative to surgery and external radiotherapy, with satisfactory long term biochemical control rates and limited complications. © 2002 Éditions scientifiques et médicales Elsevier SAS.

Cite

CITATION STYLE

APA

Chauveinc, L., Flam, T., Solignac, S., Rosenwald, J. C., Thiounn, N., Firmin, F., & Cosset, J. M. (2002). Les indications de la curiethérapie de prostate par implantation permanente. Cancer/Radiotherapie. Elsevier Masson SAS. https://doi.org/10.1016/S1278-3218(02)00163-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free